I think its important to remind folks the "general" order of things. Some of the below overlap, happen simultaneously, or occur in a slightly modified order. Trial completion is a broad term that means different things to different folks.

250 non-adjudicated first occurrence 3-point MACE events are reached

Dosing with placebo or apabetalone ends upon reaching 250 non-adjudicated events

Patient safety follow up visits occur during subsequent ~ 2 months after dosing ends. During safety follow up it is estimated that another ~20 events may occur. Importantly, these are during the non-dosing period.

Adjudication of the original 250 events and the additional ~ 20 events. Does adjudication start after dosing ends or only after patient follow up period is over? 

Top-line data announced, which will contain at minimum statement of whether BETonMACE achieved or failed to achieve primary endpoint with statistical significance. 

Full data presented at major conferences potentially starting as early as May 2019 (unless March ACC 2019 is in play). Likely that MACE data presented as separate conference from diabetes, renal and cognition data.